UK govt announces HPV vaccine timetable
The UK government has announced the addition of routine human papillomavirus (HPV) vaccination to the National Health Service's immunization program of girls aged 12-13 years. The Secretary of State for Health, Alan Johnson, announced the launch of the scheme from September 2008.
The HPV vaccine would not be compulsory, but would be "offered" to girls in the target age groups. The Department of Health announcement did not express a preference for either of the two HPV vaccines presented on the market: US drug major Merck & Co's Gardasil or UK-based world number two drugmaker GlaxoSmithKline's Cervarix.
The Health Secretary also confirmed that there would be a two-year catch up campaign starting in fall 2009, for girls up to 18 years. The routine program could cost up to L100.0 million ($202.8 million) per year and the catch up operation could add up to L200.0 million in fiscal 2009/10 and 20010/11. However, the Department of Health also stated its intention "to negotiate a reduction in vaccine price during the procurement process."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze